Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer

被引:0
|
作者
Nathalie Harder
Maria Athelogou
Harald Hessel
Nicolas Brieu
Mehmet Yigitsoy
Johannes Zimmermann
Martin Baatz
Alexander Buchner
Christian G. Stief
Thomas Kirchner
Gerd Binnig
Günter Schmidt
Ralf Huss
机构
[1] Definiens AG,Department of Urology
[2] Institute for Pathology,undefined
[3] Ludwig-Maximilians-University,undefined
[4] Ludwig-Maximilians-University,undefined
[5] Carl Zeiss Meditec AG,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tissue Phenomics is the discipline of mining tissue images to identify patterns that are related to clinical outcome providing potential prognostic and predictive value. This involves the discovery process from assay development, image analysis, and data mining to the final interpretation and validation of the findings. Importantly, this process is not linear but allows backward steps and optimization loops over multiple sub-processes. We provide a detailed description of the Tissue Phenomics methodology while exemplifying each step on the application of prostate cancer recurrence prediction. In particular, we automatically identified tissue-based biomarkers having significant prognostic value for low- and intermediate-risk prostate cancer patients (Gleason scores 6–7b) after radical prostatectomy. We found that promising phenes were related to CD8(+) and CD68(+) cells in the microenvironment of cancerous glands in combination with the local micro-vascularization. Recurrence prediction based on the selected phenes yielded accuracies up to 83% thereby clearly outperforming prediction based on the Gleason score. Moreover, we compared different machine learning algorithms to combine the most relevant phenes resulting in increased accuracies of 88% for tumor progression prediction. These findings will be of potential use for future prognostic tests for prostate cancer patients and provide a proof-of-principle of the Tissue Phenomics approach.
引用
收藏
相关论文
共 50 条
  • [41] Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study
    Rakauskas, Arnas
    Tawadros, Thomas
    Lucca, Ilaria
    Herrera, Fernanda
    Bourhis, Jean
    Burruni, Rodolfo
    Gomes, Maria Natal
    Codeluppi, Caroline
    Jolliet, Laura
    La Rosa, Stefano
    Meuwly, Jean Yves
    Jichlinski, Patrice
    Berthold, Dominik
    Valerio, Massimo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (04) : 416 - 422
  • [42] IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer
    Graff, Pierre
    Portalez, Daniel
    Lusque, Amelie
    Brun, Thomas
    Aziza, Richard
    Khalifa, Jonathan
    Roumiguie, Mathieu
    Ranty, Marie-Laure Quintyn
    Filleron, Thomas
    Bachaud, Jean-Marc
    Malavaud, Bernard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (04): : 903 - 911
  • [43] STEREOTACTIC BODY RADIATION THERAPY IN LOW- AND INTERMEDIATE-RISK PROSTATE CANCER: RESULTS OF PHASE II STUDY
    Franzese, Ciro
    D'agostino, Giuseppe Roberto
    Liardo, Rocco Luca Emanuele
    Reggiori, Giacomo
    Navarria, Pierina
    Cristina, Iftode
    De Rose, Fiorenza
    Franceschini, Davide
    Tozzi, Angelo
    Comito, Tiziana
    Ascolese, Anna Maria
    Tomatis, Stefano
    Cozzi, Luca
    Scorsetti, Marta
    ANTICANCER RESEARCH, 2016, 36 (05) : 2545 - 2545
  • [44] The Long-term Experience of Permanent Seed Implant Monotherapy in Low- and Intermediate-Risk Prostate Cancer
    Vigneault, E.
    Martin, A.
    Foster, W.
    Aubin, S.
    Despres, P.
    Beaulieu, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S367 - S367
  • [45] Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer
    Hu, Xuanhan
    Miao, Jia
    Huang, Jiaqing
    Qian, Lin
    Zhang, Dahong
    Wei, Haibin
    CURRENT ONCOLOGY, 2022, 29 (10) : 7964 - 7978
  • [46] Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance
    Whalen, Michael J.
    Pak, Jamie S.
    Lascano, Danny
    Ahlborn, David
    Matulay, Justin T.
    McKiernan, James M.
    Benson, Mitchell C.
    Wenske, Sven
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : E425 - E435
  • [47] Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer
    Gonnissen, Annelies
    Isebaert, Sofie
    Perneel, Christiaan
    McKee, Chad M.
    Verrill, Clare
    Bryant, Richard J.
    Van Utterbeeck, Filip
    Lerut, Evelyne
    Haustermans, Karin
    Muschel, Ruth J.
    BMC CANCER, 2017, 17
  • [48] Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy
    Cheung, R
    Tucker, SL
    Lee, AK
    De Crevoisier, R
    Dong, L
    Kamat, A
    Pisters, L
    Kuban, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (04): : 993 - 1002
  • [49] Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer
    Annelies Gonnissen
    Sofie Isebaert
    Christiaan Perneel
    Chad M. McKee
    Clare Verrill
    Richard J. Bryant
    Filip Van Utterbeeck
    Evelyne Lerut
    Karin Haustermans
    Ruth J. Muschel
    BMC Cancer, 17
  • [50] Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients
    Funk, R. K.
    Davis, B. J.
    Mynderse, L. A.
    Wilson, T. M.
    Deufel, C. L.
    Furutani, K. M.
    Pisansky, T. M.
    Haddock, M. G.
    Choo, C. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E213 - E214